Comparing Low-Dose Rosuvastatin Plus Ezetimibe to High-Dose Rosuvastatin for Patients With Acute Myocardial Infarction After Percutaneous Coronary Intervention
Led by Kiyuk Chang, MD,PhD · Updated on 2025-07-30
3548
Participants Needed
7
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate whether using a combination of low dose rosuvastatin 5 mg and ezetimibe 10 mg is not less effective than using a higher dose of rosuvastatin 20 mg alone in reducing major adverse cardiac events for patients with acute myocardial infarction treated with percutaneous coronary intervention. Previous studies have shown the importance of lowering LDL cholesterol in reducing heart disease risk, but the combined treatments clinical effectiveness needs further study.
Participants will be randomly assigned to receive either rosuvastatin 5 mg plus ezetimibe 10 mg once daily or rosuvastatin 20 mg once daily for 24 months. This open-label trial compares the two regimens over two years to assess their impact on heart-related outcomes. The trial is led by Kiyuk Chang, MD, PhD.
During the study, participants will be monitored for major adverse cardiovascular events over 24 months, including death, heart attacks, strokes, and need for revascularization. Additional assessments include LDL cholesterol levels at 3 months, medication adherence, muscle symptoms, new diabetes onset, and cataract occurrence. Safety and effectiveness data will be collected regularly to understand the treatments impact over the two-year period.
CONDITIONS
Brief Title
Low Dose Rosuvastatin Plus Ezetimibe Versus High-dose Rosuvastatin in AMI
Research Team
K
Kiyuk Chang, MD,PhD
E
Eun Ho Choo, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Patients diagnosed with myocardial infarction (both ST segment elevation and non-ST segment elevation) treated with percutaneous coronary intervention
Female patients of childbearing age who agree to mandatory pregnancy testing
Patients who have signed informed consent
You will not qualify if you...
Patients with life expectancy of one year or less due to cancer
Patients with chronic liver disease
Patients sensitive to ezetimibe or rosuvastatin or prohibited from taking these drugs
Pregnant or breastfeeding women
Female patients unable to use contraception
Patients on hemodialysis, peritoneal dialysis, or with kidney transplants due to end-stage renal disease
Patients who participated in other clinical trials within 3 months (except non-interventional observational studies)
Patients deemed inappropriate for the study by investigators
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - 24 months
Participants receive either low-dose rosuvastatin plus ezetimibe or high-dose rosuvastatin daily to manage acute myocardial infarction after percutaneous coronary intervention.
Regular visits throughout 24 months for treatment monitoring
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Study of Adults With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
Tracking Heart and Health Outcomes Over Time
Study of Ziltivekimab Compared to Placebo to Reduce Heart Vessel Plaque After a Heart Attack
Evaluating AI Software Accuracy for Heart Pumping Function Using the Peerbridge COR ECG Wearable Monitor
Comparison of Rivaroxaban and Warfarin for Treating Left Ventricular Blood Clots After Heart Attack in Nepal
A Randomized Study at a Tertiary Cardiac Center
Studying Anxiety, Stress, and PTSD After a Heart Attack in Adults Aged 19 to 90
Study of Ticagrelor Alone Compared to Ticagrelor Plus Aspirin in Adults With Medically Treated Myocardial Infarction
Genetic-Guided Early Switch to Low-Potency Single Antiplatelet Therapy Versus High-Potency Therapy to Reduce Bleeding in High-Risk Patients After Acute Coronary Syndrome
Barts Revascularisation Registry to Understand Patient Characteristics and Outcomes in Coronary Artery Disease at Barts Heart Centre
Barts Sex-CAD Database Studying Sex Hormones and Inflammation in Coronary Artery Disease to Understand Differences in Women and Men
Real-World Study of Patients Aged 16 and Older with Myocardial Infarction and Non-Obstructive Coronary Arteries MINOCA
Tracking Diagnosis and Outcomes at Barts Health NHS Trust
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
High-Intensity Statin versus Upfront Equivalent-Dose Combination of Moderate-Intensity Statin with Ezetimibe Following Acute Myocardial Infarction (ROSUZET-AMI): protocol of a multicentre, open-label, randomised non-inferiority trial.